Thanks Vinn - interesting reading as always.
One great aspect of meso's deal with ceph was the US$130M upfront payment, cash in the bank regardless of the takeover negotiations and outcome. Also limiting the alliance to selected neurologic and cardiovascular products gives mesoblast plenty of options on how to bring the other products to market.
While the deal with cephalon gave the market more confidence in mesoblast I can't help but think mesoblast is the company holding all the cards - given its strong management and product pipeline. I wouldn't be surprised if the board of directors aren't the least bit concerned about valeant's interest in cephalon. Whatever happens mesoblast wins, imo.
Thanks Vinn - interesting reading as always.One great aspect of...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.12 |
Change
0.010(0.90%) |
Mkt cap ! $1.250B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.12 | $1.08 | $1.644M | 1.507M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 26491 | $1.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.12 | 115836 | 17 |
View Market Depth
| Last trade - 12.41pm 19/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |